ADC Therapeutics SA (ADCT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.45 |
| Open | 6.41 |
| Bid | 6.89 x 1300 |
| Ask | 6.95 x 1100 |
| Day's Range | 6.18 - 7.01 |
| 52 Week Range | 6.18 - 32.00 |
| Volume | |
| Avg. Volume | 204,021 |
| Market Cap | 538.442M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.54 |
| Earnings Date | May 09, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADCT
Related Research
- ADC Therapeutics SAAnalyst Report: Adtran Inc.Based in Huntsville, Alabama, Adtran produces a broad range of copper- and fiber-based network access products for carriers and enterprises. The company used its early successes in the ISDN and HDSL markets to enter markets including DSL, IP, and carrier Ethernet. Product offerings include integrated access devices, optical multiplexers, Ethernet switches, access routers and network management software.RatingFair ValueEconomic Moat6 days agoArgus Research
- Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
LAUSANNE, Switzerland, May 12, 2022--ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation at the European Hematology Association 2022 Hybrid Congress (EHA2022), which will be held virtually and in Vienna, Austria from June 9-12, 2022.
- Zacks
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
LAUSANNE, Switzerland, May 09, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today reported financial results for the first quarter ended March 31, 2022 and provided business updates.
